Pradaxa Lawsuit Information: Excessive Bleeding From Pradaxa Has No Antidote and Can Cause Death by Texas Pradaxa Lawyer Jason Coomer

Pradaxa Lawsuit Information: The Blood Thinner Pradaxa Can Cause Excessive Bleeding and Has No Known Antidote or Reversal Agent Which Can Cause Death in Patients Taking the Blood Thinner by Texas Pradaxa Lawyer Jason Coomer

Pradaxa has been marketed as a new and improved blood thinner to replace existing successful blood thinners.  Pradaxa has the usual side effects and health risks of other blood thinners which includes excessive bleeding.  However, unlike older blood thinners, Pradaxa has two important differences: 

• Pradaxa has no known reversal agent or antidote, and

• There is no standard method with which to measure the anticoagulant effects of Pradaxa.

These key differences can cause persons on Pradaxa to experience a build up or overdose of the drug, excessive bleeding, and ultimately the person's death.  For more information on this topic, please feel free to send an e-mail message to Pradaxa Lawyer, Jason Coomer.

Pradaxa Has Been Marketed As A New And Improved Blood Thinner That Has Been Added To Numerous Hospital Formularies As An Established Blood Thinner Allowing Pradaxa To Rapidly Gain Market Share and Expanding Its Use

Pradaxa (dabigatran etexilate mesylate) is a direct thrombin inhibitor anticoagulant, which became FDA-approved on October 29, 2010. Pradaxa reduces the risk of stroke and systemic embolism in patients with non-valvular atrial fibrillation. Pradaxa is being marketed to be prescribed and used to replace existing successful blood thinners such as Warfarin (Coumadin).  Within the first seven months after Pradaxa's approval, more than 250,000 patients were prescribed Pradaxa.  In July 2011, Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) announced that Pradaxa (dabigatran etexilate mesylate) capsules had been added to hospital formularies at 49 of the top 50 cardiology and heart surgery hospitals in the United States.  In other words Pradaxa was added as the blood thinner of choice in formularies that insure about 90 percent of covered lives in the U.S.

Boehringer Ingelheim has successfully marketed Pradaxa as an improvement over other blood thinners.  However, Pradaxa has already led to hundreds of reports of deaths and many other serious life-threatening injuries.

Large Drug Companies That Influence Standards of Care Including Hospital Formularies Through Marketing Fraud and Fraudulent Research Can Be Held Liable For Medicaid Fraud and Medicare Fraud Through Whistleblower Reward Lawsuits

Many health care professions have become aware of the strong influence that drug companies now have in determining community standards of care for medication use in patients.  These drug companies often push drug samples into many hospitals and use powerful forms of manipulation including biased research, influencing key medical doctors, and kickbacks to get their drugs placed on hospital formularies.

Whistleblowers that are the first to file on these fraudulent practices can expose fraud and obtain large whistleblower rewards for exposing fraud. These medical professionals and pharmaceutical professionals can also have a drug formulary fraud whistleblower reward lawyer confidentially review a potential case prior to stepping forward.  For more information on Drug Formulary Fraud Whistleblower Reward Lawsuits, please feel free to go to the following web page: Drug Formulary Fraud Whistleblower Reward Lawsuit.

Pradaxa Lawsuit Information: The Blood Thinner Pradaxa Can Cause Excessive Bleeding and Has No Known Antidote or Reversal Agent Which Can Cause Death in Patients Taking the Blood Thinner

For more information on this topic, please feel free to go to the following web page: Pradaxa Lawsuit Information or please feel free to send an e-mail message to Pradaxa Lawyer, Jason Coomer.